GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (FRA:7NS0) » Definitions » Net Income From Continuing Operations

Palisade Bio (FRA:7NS0) Net Income From Continuing Operations : €-12.47 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Palisade Bio's net income from continuing operations for the three months ended in Mar. 2024 was €-3.25 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €-12.47 Mil.

Palisade Bio Net Income From Continuing Operations Historical Data

The historical data trend for Palisade Bio's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio Net Income From Continuing Operations Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
-8.49 -23.56 -13.46 -11.28

Palisade Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.19 -3.13 -3.37 -2.72 -3.25

Palisade Bio Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palisade Bio (FRA:7NS0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (FRA:7NS0) » Definitions » Net Income From Continuing Operations
Comparable Companies
NAVB TCON WINT SNGX XCUR RGBP TSOI FRTX HOTH THER OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
PALI:USA
Address
5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008
Website
https://www.palisadebio.com
Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Palisade Bio (FRA:7NS0) Headlines

No Headlines